66598-81-0Relevant articles and documents
Meta C-H Arylation of Electron-Rich Arenes: Reversing the Conventional Site Selectivity
Liu, Luo-Yan,Qiao, Jennifer X.,Yeung, Kap-Sun,Ewing, William R.,Yu, Jin-Quan
supporting information, p. 14870 - 14877 (2019/10/02)
Controlling site selectivity of C-H activation without using a directing group remains a significant challenge. While Pd(II) catalysts modulated by a mutually repulsive pyridine-type ligand have been shown to favor the relatively electron-rich carbon centers of arenes, reversing the selectivity to favor palladation at the relatively electron-deficient positions has not been possible. Herein we report the first catalytic system that effectively performs meta C-H arylation of a variety of alkoxy aromatics including 2,3-dihydrobenzofuran and chromane with exclusive meta site selectivity, thus reversing the conventional site selectivity governed by native electronic effects. The identification of an effective ligand and modified norbornene (NBE-CO2Me), as well as taking advantage of the statistics, are essential for achieving the exclusive meta selectivity.
An efficient and practical enantiospecific synthesis of methyl chromanone- and chroman-2-carboxylates
Kim, Dong Woon,Maqusood Alam,Lee, Young Hun,Khan, M. Naseer A.,Zhang, Yong,Lee, Yong Sup
, p. 912 - 917 (2015/08/24)
Chromanone-2-carboxylates and chroman-2-carboxylates are useful building blocks for the synthesis of a variety of bioactive compounds, such as repinotan, fidarestat, and nebivolol. An efficient and practical enantiospecific synthesis of chromanone-2-carboxylates and chroman-2-carboxylates has been accomplished using intramolecular Mitsunobu etherification of methyl (S)-2-hydroxy-4-oxo-4-(2′-hydroxy)phenylbutanoates derived from l-malic acid.
NEW SOMATOSTATIN RECEPTOR SUBTYPE 4 (SSTR4) AGONISTS
-
Page/Page column 143, (2014/12/12)
The invention relates to 3-aza-bicyclo[3.1.0]hexane-6-carboxylic acid amide derivatives of general formula (I), which are agonists of somatostatin receptor subtype 4 (SSTR4), useful for preventing or treating medical disorders related to SSTR4. In addition, the invention relates to processes for preparing pharmaceutical compositions as well as processes for manufacture of the compounds according to the invention.